Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1064 and MK-6096 Effects on Polysomnography
NCT02549027Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of mk-1064 in Insomnia, sponsored by Merck & Co. Primary endpoints: Latency to Persistent Sleep Following Single Doses of MK-1064 and Placebo, Latency to Persistent Sleep Following Single Doses of MK-6096 and Placebo and 2 more. Started Nov 2009; status: completed.
02
Drugs
mk-1064
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT02549027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549027.